Abstract Number: 1674 • ACR/ARHP Annual Meeting 2017
Combining Medications That Lower Systemic Oxidative Stress Is Associated with Less Atherosclerosis in Systemic Lupus Erythematosus
Background/Purpose: No single medication has been demonstrated as effective in reducing atherosclerosis or cardiovascular events in systemic lupus erythematosus (SLE), possibly due to the…Abstract Number: 772 • ACR/ARHP Annual Meeting 2016
Effect of HMG-CoA Reductase Inhibitor Drugs (Statins) on Systemic Lupus Erythematosus Disease Activity: A Systematic Review and Meta-Analysis
Background/Purpose: Statins have been shown to have anti-inflammatory and immunomodulatory effects. In vitro studies show that these drugs inhibit inflammatory cells, decrease the expression of…Abstract Number: 887 • ACR/ARHP Annual Meeting 2013
Atherosclerosis and Cardiovascular Disease In Systemic Lupus Eryhematosus Are Related To An Inflammatory/Oxidative Status Linked To The Autoimmune Condition and The Clinical Activity Of The Disease. Effect Of Statins Treatment
Background/Purpose: Atherosclerosis (AT) and cardiovascular disease (CVD) are enhanced systemic lupus erythematosus (SLE). Although there is evidence that statins have anti-inflammatory properties, their mechanism of…Abstract Number: 1824 • ACR/ARHP Annual Meeting 2012
Do Statins Reduce the Incidence of Connective Tissue Disease? A Retrospective Cohort Study
Background/Purpose: Due to their anti-inflammatory effects, statins were proposed to lower the incidence of connective tissue diseases (CTD). The objective of this study is to…
ACR Meeting Abstracts